Poloxamer Hydrogels for Biomedical Applications by Russo, E. & Villa, C.
pharmaceutics
Review
Poloxamer Hydrogels for Biomedical Applications
Eleonora Russo * and Carla Villa
Department of Pharmacy, University of Genoa, Viale Benedetto XV, 16132 Genova, Italy; villa@difar.unige.it
* Correspondence: russo@difar.unige.it
Received: 31 October 2019; Accepted: 6 December 2019; Published: 10 December 2019


Abstract: This review article focuses on thermoresponsive hydrogels consisting of poloxamers which
are of high interest for biomedical application especially in drug delivery for ophthalmic, injectable,
transdermal, and vaginal administration. These hydrogels remain fluid at room temperature but
become more viscous gel once they are exposed to body temperature. In this way, the gelling system
remains at the topical level for a long time and the drug release is controlled and prolonged. Poloxamers
are synthetic triblock copolymers of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene
oxide) (PEO-PPO-PEO), also commercially known as Pluronics®, Synperonics® or Lutrol®. The
different poloxamers cover a range of liquids, pastes, and solids, with molecular weights and
ethylene oxide–propylene oxide weight ratios varying from 1100 to 14,000 and 1:9 to 8:2, respectively.
Concentrated aqueous solutions of poloxamers form thermoreversible gels. In recent years this type
of gel has arouse interest for tissue engineering. Finally, the use of poloxamers as biosurfactants is
evaluated since they are able to form micelles in an aqueous environment above a concentration
threshold known as critical micelle concentration (CMC). This property is exploited for drug delivery
and different therapeutic applications.
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1. Introduction
The word “hydrogel”, according to Lee, Kwon and Park is due to an article published in 1894, but
the first crosslinked network material that appeared in literature and that has been described by its
typical hydrogel properties, was a polyhydroxyethylmethacrylate (HEMA) hydrogel developed much
later, in 1960, by O. Wichterle and D. Lim, with the aim of using it in permanent contact applications
with human tissues, i.e., as soft contact lenses [1].
Since then, hydrogels have been used as systems for drug controlled delivery, to facilitate the
localized, sustained and prolonged release of a drug, thereby decreasing the number of administrations,
avoiding side effects and following low doses [2].
The most widely studied environmentally responsive systems were temperature sensitive
hydrogels, in which physical entanglements, hydrogen bonding, and hydrophobic interactions
are the main features that constitute the crosslinks. Two different types of thermo-sensitive hydrogels
exist that undergo gelation either by cooling below the upper critical gelation temperature (UCGT)
or by heating above the lower critical gelation temperature (LCGT), respectively. Hydrogels with
LCGT behavior and sol-to-gel transition at 37 ◦C have gained increasing attention in the biomedical
field as carriers for cells, drugs, and biomolecules, since they allow encapsulation in mild conditions
(temperature ≤ 37◦C) [3].
Poloxamers and poloxamines are examples of these LCGT biocompatible thermoreversible
hydrogels that were introduced in the 1950s by BASF (Iselin, NJ, USA) when they started being used
for detergent development, but also in other areas, like agriculture, food, and paints [4].
Poloxamers or Pluronics® are a class of water-soluble nonionic triblock copolymers formed by
polar (poly ethylene oxide) and non-polar (poly propylene oxide) blocks. which confer amphiphilic and
Pharmaceutics 2019, 11, 671; doi:10.3390/pharmaceutics11120671 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2019, 11, 671 2 of 17
surface active properties to the polymers. Their aqueous solutions undergo sol-to-gel transition with
increasing the temperature above a LCGT; moreover, the coexistence of hydrophilic and hydrophobic
monomers into block copolymers allows the formation of ordered structures in solution, the most
common of these being the micelles. The formation of micelles in solution is a reversible and dynamic
process useful for encapsulating hydrophobic drugs and delivering them into an aqueous environment.
They can be considered as smart polymers, for their stimuli-sensitive properties, due to the different
behaviors of these polymers since they can modify their structure in function of pH, temperature and
salt concentration [5]. For this reason, a variety of Pluronics is available on the market, differing for
the molecular weight of the building blocks and for the hydrophobic–hydrophilic ratio, allowing the
preparation of thermosensitive hydrogels with different properties, e.g., in terms of critical gelation
concentration (CGC) and gelation time at physiological condition [3].
Thus, poloxamers represent a convenient choice in pharmaceutical technology and biomedical
area due to their commercial availability, wide range of molecular weights, peculiar behavior and
flexibility. Poloxamers are FDA approved and listed in the US and European Pharmacopoeia; they
are non-toxic and non-irritant therefore they can be used as solubilizer, emulsifier, stabilizer, and
administered through oral, parenteral, topical routes. As wetting agents, they are useful in ointments,
suppository bases, and gels [6].
Poloxamer hydrogels use in drug release appeared at the beginning of the 1970s; they were a
response in the search for new safer and faster treatments for the delivery of highly-effective therapeutic
agents to a target cell, even if they have poor mechanical properties such as low tensile strength and low
Young’s modulus that limit their practical applications, sometimes even as medical device coatings [7].
Analysis of recent literature covering a range of treatment pathways and diseases, reveals a major
emphasis on “smart” drug carriers developed with poloxamers. The different range of potential
delivery methods is highlighted in this review by discussing how the poloxamer solution behavior
enables multiple formulation processing routes, drug-encapsulating structures, and engagement with
physiological barriers to drug passage.
The first research work concerned the treatment of thermal burns [8] followed by researches
on the release of hormones [9], tetracycline [10], proteins [11], and more recently for norcantharidin
delivery [12], heparin [13], and anti-HIV drugs [14]. In the last twenty years the numbers of papers
related to poloxamer hydrogels for biomedical applications is exponentially increased (Figure 1).
Figure 1. Histogram showing the increase in publications related to the keywords “poloxamer hydrogel”
in Science Direct database during the past twenty years.
More recently such hydrogels have become especially attractive to the new field of “tissue
engineering” as matrices for repairing and regenerating a wide variety of tissues and organs [15].
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They have been successfully employed as scaffold-forming materials for cell printing technology,
a computer-aided tissue engineering technology based on the layered deposition of cellularized
hydrogels to form complex 3D constructs [16–18].
In this review the poloxamer hydrogels will be taken into consideration, giving an overview of
their use as drug delivery systems (DDS) in different routes of administration, especially ophthalmic,
transdermal, and vaginal ones. Finally, this paper focused on their potential in tissue and membrane
regeneration, in the field of biomedical engineering and their application as micellar systems for gene
delivery and cancer therapy.
2. Poloxamers
2.1. Poloxamers Properties
These polymers are synthetic triblock copolymers of poly(ethylene oxide)-b-poly(propylene
oxide)-b-poly(ethylene oxide) (PEO-PPO-PEO) (Figure 2).
Figure 2. Chemical formula for poloxamers: x and y are the lengths of PEO and PPO: poly(ethylene
oxide) and poly(propylene oxide) chains, respectively.
They are synthesized through the sequential addition of PO and EO monomers in the presence of
an alkaline catalyst, such as sodium or potassium hydroxide, obtaining different copolymers with a
different number of hydrophilic EO and hydrophobic PO units, which are also characterized by their
distinct hydrophilic–lipophilic balance (HLB) value. Changes in the copolymer composition (PPO/PEO
ratio) and molecular weight (PEO and PPO block length) during synthesis leads to macromolecular
surface active agents with specific properties suitable in various technological areas.
Poloxamers appear in the form of liquids, pastes, and solids, depending on their molecular weights
varying from 1100 to 14,000, offering a pool of more than 50 amphiphilic, water-soluble and polymorphic
materials. Their water solubility is subjected by different ratio (1:9 to 8:2) between the chain of propylene
oxide (PO) and ethylene oxide (EO) with hydrophobic and hydrophilic behavior, respectively [16].
These differences also alter the in vivo properties and interactions with cells and cell membranes, and
provides high potential for the design of innovative nanomedicines and new biomaterials.
Poloxamers were the first block copolymers produced for industrial purposes, synthesized by
Wyandotte Chemical Corporation in the late 1940s. Today they are commercially known by the trade
names Pluronics®, Lutrol®, Kolliphor® (BASF), Antarox® (Rhodia), and Synperonics® (Croda).
The original manufacturer BASF introduced a specific nomenclature for Pluronics consisting of a
letter indicating the morphism of each copolymer: L (for liquid), P (for paste) or F (for flakes) followed
by a number referring to the molecular weight of the PPO block (the first one or two) and the weight
fraction of the PEO block (the last one).
For example, P123 and F127 have the same molecular weight of PPO (in the order of 4000) but
P123 has 30% of PEO and F127 70% of PEO [17].
The physicochemical characteristics and applications of Poloxamers were firstly reviewed
extensively by Alexandridis and Hatton in 1995 [16]. In Figure 3, a 3D poloxamer modified pluronic grid
showing the distribution of different copolymers, gathered according their physical state, is reported.
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Figure 3. Poloxamers 3D distribution according to physical state (solid flakes = magenta; paste =
yellow; liquid = blue), weight percentage of POE chains and molecular mass of the PPO groups
(adapted from [16]).
The most significant physical properties of most common poloxamers, are reported in Table 1:
average molecular weight, melting point expressed in ◦C, viscosity (Pa·s) measured at 25 ◦C, 60 ◦C,
and 50 ◦C for pastes, liquids, and solids, respectively, surface tension at 0.1% at 25 ◦C (dyn cm−1),
hydrophilic–lipophilic balance (HLB) [4,17,19,20].
Table 1. Properties of the most common poloxamer poly(ethylene oxide)-b-poly(propylene













P105 L35 50 1900 7 0.375 49 18–23
P108 F38 80 4700 48 0.260 52 >24
P122 L42 20 1630 −26 0.280 46 7–12
P123 L43 30 1850 −1 0.310 47 7–12
P124 L44 40 2200 16 0.440 45 12–18
P182 L62 20 2500 −4 0.450 43 1–7
P183 L63 30 2650 10 0.490 43 7–12
P184 L64 40 2900 16 0.850 43 12–18
P185 P65 50 3400 27 0.180 46 12–18
P188 F68 80 8400 52 1.000 50 >24
P212 L72 20 2750 −7 0.510 39 1–7
P215 P75 50 4150 27 0.250 43 12–18
P217 F77 70 6600 48 0.480 47 >24
P234 P84 40 4200 34 0.280 42 12–18
P235 P85 50 4600 34 0.310 42 12–18
P237 F87 70 7700 49 0.700 44 >24
P238 F88 80 11,400 54 2.300 48 >24
P288 F98 80 13,000 58 2.700 43 >24
P333 P103 30 4950 30 0.285 34 7–12
P334 P104 40 5900 32 0.390 33 12–18
P335 P105 50 6500 35 0.750 39 12–18
P338 F108 80 14,600 57 2.800 41 >24
P402 L122 20 5000 20 1.750 33 1–7
P403 P123 30 5750 31 0.350 34 7–12
P407 F127 70 12600 56 3.100 41 18–23
Commonly used poloxamers include P188 (F-68 grade), P237 (F-87 grade), P338 (F-108 grade),
and P407 (F-127 grade) types, which are freely soluble in water.
Pharmaceutics 2019, 11, 671 5 of 17
2.2. Poloxamers Behavior
The aqueous solution properties of poloxamers have been intensely studied and thoroughly
reviewed owing to their unique behavior and benefit to myriad applications.
In water solutions, the amphiphilic character of copolymers lead the macromolecule to
self-aggregate into micelles with an inner core constituted by hydrophobic blocks and an outer
shell constituted by hydrophilic units. They are nano-sized structures, normally between 10 and
200 nm that appears at the critical micellization concentration (CMC) and at critical micellization
temperature (CMT). CMC value of poloxamer aqueous solutions decreases with increasing temperature
and number of PEO segments, indicating that polymers with a larger hydrophobic (PPO) domain form
micelles at lower concentrations and temperatures [21].
Poloxamer water solutions exhibit temperature sensitivity, in particular a “thermoreversible
gelation” [21] for sufficiently concentrated samples; they show a sol-gel transition around 37 ◦C
(physiological temperature) and gel-sol transition around 50 ◦C, being able to produce thermoreversible
gels, some already approved by the Food and Drug Administration, which present great interest in food
additives, drug delivery carriers in cosmetics, pharmaceutical ingredients, and tissue engineering [5,17]
Several mechanisms have been proposed for this behavior, the first one was related to the gel
transition that was due to changes in micellar properties (Figure 4).
Figure 4. Schematic representation for hydrogel formation.
Thanks to their core–shell architecture, the hydrophobic core can act as a drug-loading site,
creating a space for the encapsulation of hydrophobic drugs through the establishment of physical
or chemical interactions. The properties of the outer shell and inner core have an influence in the
drug release, that can promote an easier or sustained release of the drug. Due the properties above
mentioned, polymeric micelles can transport several drugs, improving the circulation time, as well as
the enhanced permeability and retention effect. Moreover, these systems exhibit low-risk of chronic
toxicity since the polymeric micelles are disassembled in vivo, in single polymer chains that can be
excreted by kidneys.
In order to prepare polymeric micelles for drug encapsulation, different methods can be
used, however, the more common are the direct dissolution, dialysis, evaporation or film method,
freeze-drying, microphase separation, and the oil-in-water emulsion [22].
The method depends, mostly, on the solubility of the copolymer and the drug in an aqueous
medium. Some other aspects are also important to an efficient drug incorporation, such as copolymer
characteristics, molecular weight and HLB. The structural and chemical characterization of polymeric
micelles are important features to take into account in the development of these nanocarriers, since they
have a direct influence on the efficiency of these drug release forms, in terms of size, polydispersion
index, zeta potential, encapsulation efficiency (EE), and drug loading capacity (DL) [23].
Other researchers [24] discussed gelation as a function of thermodynamical parameters. The
enthalpy of gelation depends on CMC and temperature, the value change in the case of poloxamers
gelation is unfavorable unlike the gelatine gelation where a great enthalpy change occurred.
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The useful concentration for gel formation is the same as for poloxamers with the same PPO/PEO
ratio and it decreases with the increasing of polymer molecular weight, denoting the significance of
this parameter. While the presence of electrolytes reduces gel transition temperature, enthalpy of gel
formation is not significantly changed by the addition of other substances. This behavior suggests that
entropy plays the major role in the gelation process.
For all these behaviors, the poloxamers were used for the study and for the development of
innovative pharmaceutical forms in different administration routes.
3. Drug Delivery Systems (DDS)
Poloxamer sol-gel reversible hydrogels have attracted the attention for practical biomedical and
pharmaceutical applications because of constituents solubility, biocompatibility with biological systems
and easy administration of pharmaceutical formulations. The pharmaceutical and biomedical fields
covered by the use of poloxamers including solubilization of hydrophobic drugs, controlled release,
biomacromolecule delivery (e.g., proteins and genes) and tissue engineering.
Most applications involve the use of Poloxamer P407 and include delivery of protein/peptide
drugs [25], such as insulin [26], interleukin-2 [27], epidermal growth factor [28], bone morphogenic
protein [29], fibroblastic growth factor, and endothelial cell growth factor [30].
In recent years these hydrogels have been used as carriers for most routes of administration,
the most interesting are discussed below.
3.1. Poloxamers for Oftalmic Administration
The thermoreversible gels have shown a growing interest at ocular level because they combine
peculiar characteristics: i.e., the formulation when applied is sol (it performs like eye drops) and
becomes gel with body temperature (it performs like ointment) increasing the in situ residence time.
The most well-known ocular drug delivery system is eye drops, but they have a short residence
time because they are quickly drained through the nasolacrimal route resulting in frequent dosage
regimen which leads to an increase in side effects and poor patient compliance.
Poloxamers P407 and P188 are among the most commonly used in this case for their good water
solubility, solution clearness, optimal viscosity, and ocular tissue safety.
Recent works have focused on the best formulation to obtain a hydrogel with useful features
for ocular administration and without toxicity. About this point Al Khateb et al. [31] studied two
formulations containing poloxamers, i.e., P407 and P188, with different gelation properties depending
on concentration solutions and the ratio of their mixtures. Transparent gels were obtained only in the
case of 20% w/w P407 and P188 solutions. Furthermore, these preparations were non-toxic or irritating
to the corneal mucosa and then suitable for application in ocular drug delivery.
Fathalla Z.M.A. et al. [32] studied the blend of the same two poloxamers for a controlled ocular
delivery of ketorolac tromethamine (KT). The most promising gel formulations, loaded with KT, were
those containing the mixtures of P407:P188 23:10 w/v% and 23:15 w/v% respectively. These gels do not
present toxicity and do not irritate the conjunctiva and cornea.
In recent years other polymers have been added to poloxamers-based gels to obtain different drug
release characteristics and to modify the rheological properties.
Among these works, Yu et al. [33] has to be remembered for the synthesis of a cross-linked hydrogel
system containing carboxymethyl chitosan (CMC) and poloxamer P407, where the presence of CMC
with biological properties could improve hydrogel biocompatibility. This formulation, containing
nepafenac (NP) as a model drug, showed good rheological properties at gelation temperature (32–33 ◦C)
and a sustained release of NP from hydrogel, so as to be considered a pH–temperature-responsive
ophthalmic drug delivery system.
Another approach, with good results, involved the introduction of various colloidal carrier
systems to easily load poorly soluble drugs into poloxamers hydrogels.
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Lou et al. [34] incorporated curcumin-loaded albumin nanoparticles into a hydrogel based on a
mixture of P407/P188 for local ocular administration, to treat diabetic retinopathy. This formulation,
which became a gel when exposed to eye temperature, may be applied as eye drops. Nanoparticles
provided the sustained drug release while the presence of hydrogel prolonged the in situ residence time.
Finally, Almeda et al. [35] reported the combination of lipid nanoparticles and a thermoresponsive
polymer with mucomimetic properties (poloxamer P407). The incorporated nanoparticles showed an
average size below 200 nm, a good positive zeta potential and an efficiency of ibuprofen encapsulation
of about 90%. The optimal poloxamer concentration in thermoreversible gel was 15% (w/w) Pluronic®
F-127. The formulation did not present a relevant cytotoxicity and showed a sustained release of
ibuprofen over several hours. The strategy proposed in this work can be successfully applied to
increase bioavailability and therapeutic efficacy of conventional eyedrops.
3.2. Poloxamers for Transdermal Administration
Transdermal drug delivery is a valid alternative to the oral and parenteral route because it offers
several advantages: Avoidance the hepatic first pass, good compliance by the patient, and easy
access. The most studied formulations for this route contained poloxamer P407, as a polymer, and as
drugs those with anti-inflammatory [36,37], analgesic [38], local anesthetic [39], and cardiac [40,41]
activity, rarely are present preparations containing big molecules such as arginine, vasopressin, and
insulin [42,43].
Generally in these topical preparations it is necessary to introduce an enhancer substance which is
able to facilitate the passage through the stratum corneum (thickness of 10 to 15 µm) which is the main
barrier to drug penetration.
In the last decade the penetration enhancers have been replaced by the microneedles (MNs) that
have the capacity to permeate the stratum corneum and infuse the active ingredient in the deep areas
of the skin.
Microneedles are needles similar to the ones useful for hypodermic injections but they present
different sizes: from 1–100 microns in length and 1 micron in diameter (Figure 5). They are manufactured
with silicon [44,45], metals such as stainless steel, palladium, nickel and titanium [46–48], carbohydrates
including galactose, maltose, and polysaccharide [49–51], glass [52], ceramics [53], and various other
polymers [54,55]. MNs are fabricated in backing that can be applied to the substrate like a patch
carrying different drugs by penetrating through the skin, mucosal tissue and sclera [56–59]. Their
dissolution has to be taken into consideration because it can influence drug delivery [60,61].
One of the most recent researches regards sol-gel transition property of poloxamers to obtain in
situ forming hydrogel microneedles, for the delivery of methotrexate to treat solid tumors [62]. The
use of this drug by transdermal route is generally limited by its relatively high molecular weight and
hydrophilicity. For this purpose four formulations were prepared with two different methotrexate
concentrations (0.2% and 0.4% w/w) with poloxamer P407 (20% w/w) and without, using the last
one as a control, replacing the polymer with deionized water. In this study, it was confirmed the
sol-gel transition of the formulations at skin temperature (32 ◦C), maintaining skin barrier function and
skin viscoelastic properties after administration of the formulations. In vitro drug diffusion studies,
using a Franz cell, showed that the formulations containing methotrexate (0.2% and 0.4%) without
P407 released overall drug after 22 and 35 h respectively, while the one with P407 after 72 h. For
this reason it is possible to conclude that the poloxamer-based formulations provided a steady and
sustained delivery.
In an even more recent work, the formation of depots of thermoreversible poloxamers in skin
micropores using MNs to transdermal drug delivery has been reported for the first time [63]. Sodium
fluorescein (FS) was used as model drug to study in vitro permeation at different concentrations.
In order to crate pores into the skin and to overcome the stratum corneum MNs have been used, then
the drug loaded poloxamer solution was applied to fill pores, subsequently an in situ gelation at skin
temperature of 32 ◦C occurred.
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Figure 5. Scanning electron microscopy images of microneedle arrays imaged from a lateral view (A,B)
and from the top side (C). Scale bars represent 500 µm (80×) (A,C) and 100 µm (300×) (B) (adapted
from [64]).
For this goal poloxamers P407, P237, and P338 were used at different concentrations (from 15 to
30% w/w in water) loading different amounts of fluorescein.
The formulations were characterized for their rheological properties and in situ gel formation.
The distribution of FS in skin tissue was tracked by confocal laser microscopic analysis with higher
intensity of FS in MN-treated skin tissues. The in vitro fluorescein release studies were carried out
using vertical Franz diffusion cells. The release profiles indicated that the concentration of fluorescein
(0.1%, 0.3%, and 0.5% w/w) was a variable parameter that significantly affects drug release as well as
the type of poloxamer used. In particular P338 and P237 0.1–0.3% FS-loaded formulations provided a
total drug release during 16 h while 0.5% FS-loaded provided a release for 20 h. Moreover, for a longer
time (about 24 h), the release from P407 formulations was comparable. All the poloxamers depots
started dissolving according to the dominant hydrophilic interactions and gels did not remain intact.
It was concluded that P407 provided the best release for a longer duration and it was selected as the
best drug delivery for in vitro permeation assays. These studies confirmed that drug loading is not a
limitation and permeation of FS after MN treatment was found in more controlled manner and for a
long time when compared to a permeation across untreated skin sample.
3.3. Poloxamers for Vaginal Administration
Another interesting pathway exploited in drug delivery systems is the vaginal route, allowing both
the systemic and local absorption of drugs poorly absorbed after oral administration [65–67]. The vagina
has a vast network of blood vessels that make easy the systemic absorption, avoiding deactivation at
gastrointestinal level and hepatic first pass. Mucoadhesive pharmaceutical forms have been studied for
this district due to the presence of mucus which increases permeability. The thermoreversible systems,
appropriately modified with polymers that promote mucoadhesion, allow to obtain a sustained drug
release and a good bioavailability without altering the vaginal physiology [68].
After application of poloxamers for vaginal administration occurring gelation favored a long
permanence of drugs on the administration site to promote a drug controlled release [69]. Vaginal drug
delivery is based on the exploitation of polymers which are able not only to gelify at physiological
temperature but also to adhere to the vaginal mucosa improving the in situ residence time.
A brief description of recent reports in the literature, based on poloxamer formulations by vaginal
route, is given below.
In the first work [70] the authors investigated a novel amphotericin B (AmB) release system in the
form of nanosuspension loaded into a poloxamer P407/P188 hydrogel. P407 (20% w/w) and P188 (5%
w/w) were dissolved in AmB nanosuspension, the AmB NPs thermogel were characterized regarding
nanoparticle features (particle size, zeta potential, morphology) and gel behavior (rheology, stability,
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in vitro drug release, and in vitro and in vivo anti-Candida efficiency). The nanosuspension-gel
combination has been necessary because nanoparticles alone tended to aggregate while they were
more stable in the poloxamer hydrogel. When compared with other biodegradable thermosensitive
hydrogel, such as polyester-based gels, poloxamer were not capable of an in vivo degradation. This
property is really suitable for vaginal delivery because it means grater safety in use. Another very
important element in the development of vaginal formulations was mucoadhesion; poloxamers have
lower adhesion properties compared to compounds such as Carbopol, the addition of some bioadhesive
materials into P407/P188 thermogel would be a feasible path [71–73]. Finally, the in vivo anti-Candida
assay showed a better antifungal efficiency of AmB in the thermoreversible gel when compared with
commercial effervescent tablets at the same drug dose (2.5 mg/Kg).
A second paper [74] described a novel vaginal delivery strategy consisting of two pharmaceutical
forms placed together to give an expansible thermal gelling aerosol foam (ETGFA) that combined the
advantages of foam and gel penetration and carrier retention in vaginal canal, respectively.
ETGA was prepared adding an optimized amount of P407 (18–22% w/w) and P188 (0–5%
w/w), achieved by evaluating the gelation temperature, the adhesive agents (arabic gum, sodium
carboxymethyl cellulose, sodium alginate, and xanthan gum) and silver nanoparticles to obtain a
drug concentration of 1% w/w. To study a better performance in foam expansion and duration,
propane/butane 80/20 v/v and dimethyl ether were compared as propellants. The formulation was
characterized in regards of rheology, foam expansion, adhesiveness and drug release. ETGA showed a
better extended drug release (over 4 h) dose –dependent antimicrobial effects on the vaginal flora and
no tissue irritation when compared to a commercial antimicrobial gel. These results indicated that
ETGA could be a suitable formulation for vaginal drug delivery.
4. Tissue Regeneration Scaffolders
Tissue engineering, in this last decade, has emerged in the biomedical field because it allows
researchers to create specific devices that represent in vivo tissues that can be replaced or increased to
address current therapeutic challenges [75].
Poloxamers have received special attention for tissue regeneration based on their biocompatibility,
low cytotoxicity, and good rheological properties [76].
In particular, the area the most explored deals with regeneration of bone tissue. The use of growth
factors such as bone morphogenetic protein-2 (BMP-2) for bone repair has been reported [77,78] but
it is very expensive and easily loose its integrity. Recently, other compounds that have received
interest were statins because they altered bone metabolism through different mechanisms [79–81].
Their bioavailability after oral administration was low and a real bone healing cannot be expected.
For this reason different delivery systems for local delivery of statins have been evaluated. The
study of incorporation of rosuvastatin (RSV)-loaded chitosan/chondroitin sulfate nanoparticles into
a thermosensitive hydrogel is reported below [82]. At first this research considered nanoparticles
preparation and optimization, thereafter it dealt with the characterization of thermosensible hydrogels.
Gel formulation consisted of poloxamer P407 (18–20% w/v), hyaluronic acid (HA) 1–3% w/v and
hydroxypropyl methylcellulose (2% w/v) to stabilize the formulation itself.
HA [83] and P407 had also positive effects on articular cartilage, simulating the regenerative
process within the joint. The study showed that gel provided a low viscosity at 4 ◦C and gelification at
35 ◦C; drug release from nanoparticles, inserted into the hydrogel, was around 60% after 48 h, while it
was completely released from nanoparticles alone within 12 h. This behavior indicated that the drug
release was controlled and sustained.
Moreover, the hydrogel formulation showed an improvement in osteoblast viability and
proliferation due to the used polymer and the biological properties of the nanoparticle delivery system.
Another paper [84] reported the design of a cryogel scaffold for the regeneration of an intervertebral
disc tissue (nucleus pulposus NP). NP is located inside the vertebral discs and has the function of
absorbing the pressure exerted on the spine and keeping the vertebrae separated. The symptoms
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of NP degeneration are pain and limited mobility of the extremities. It is composed of up to 90%
water, type II collagen and proteoglycans [85]. This study focused on the preparation of a novel
gelatin-P407 cryogel (in different ratio: 1:1,2:1, 4:1,5:1, 7:1, or 10:1 respectively) as an alternative to the
spinal fusion procedure. The composite hydrogel was tested by the following assays: Pore analysis,
swelling potential, stability, mechanical integrity and cellular infiltration. The inclusion of P407 in the
cryogel was designed to increase swelling ratio, due its hydrophilic nature, since in the NP degradation
there is a rapid water loss. All sample presented a high swelling ratio after 24 h, mechanical durability
and stability for 28 days in a body-like environment. The 7:1 and 10:1 gel scaffolds showed the most
ideal pore diameters and a profuse cell infiltration after only 14 days.
In recent years, 3D printing technology has become important in the biomedical field and in
particular the use of thermoreversible gels that with their sol-gel characteristics can be very useful in
tissue regeneration [86].
The principle on which the 3D printer is based is to lay a filament of polymeric material which is
deposited layer upon layer until the desired system is obtained in 3 dimensions.
Bioprinting systems can be classified into three types: Laser based, jetting based, and extrusion
based; recent techniques such as magnetic bioprinting and electrohydrodynamic jetting have been
used in tissue engineering.
Hydrogels requirements for 3D bioprinting of ideal engineered tissues should be the following [87]:
High porosity, rapid gelation, shape retention, and immunological issue avoidance.
Thermoreversible hydrogels have been successfully applied thanks to their gelation characteristics
as they quickly pass from sol-gel state and are also easily extruded from 3D printers [88].
P407 showed good printability [86] but it was not suitable for long-term cell viability. As reported
by the recent work [89] it is used, combined with gelatin to create a biocompatible hydrogel for vascular
channels, for molds, exploiting its excellent rheological behavior, under shear stress, and its elasticity.
In addition to bioprintability, biological properties of hydrogels played a crucial role in successful
tissues regeneration [90]. One of the major disadvantages of available hydrogel materials was that
they do not facilitate differentiation of cells into multiple linkages. Despite this, thermoresponsive
hydrogels may be very useful for tissue engineering applications and they will become part of the
advancement in bio printing technology.
5. Poloxamer as Micellar Systems
Polymeric micelles generated by poloxamers with peculiar characteristics and under specific
conditions are exploited as nanometric drug carriers [91]. They have taken hold in recent years
as they are able to solubilize poorly water-soluble drugs [36] and decrease undesirable cellular
interactions [92,93]. In this review chapter, two recent applications (gene delivery and cancer therapy)
of poloxamer micelles have been taken into account.
The development of gene delivery carriers has emerged as a promising technology in transporting
genes directly to the target site as therapeutic factors [94]. Current gene transfer vectors used in
regenerative medicine approaches included no viral [95] and viral vehicles [96]. The complexation of
DNA with cationic polymers (polyplexes) or lipids (lipoplexes) protected DNA against degradation
by nucleases and serum components creating a less negative surface charge. They can be designed
to target specific cell types through receptor–ligand interactions [97], but these systems exhibited
aggregation tendency, a low transfection efficiency and short time transgene expression levels [98]. The
use of poloxamers has been described as a tool to increase efficiency of viral gene transfer, obtaining a
localized delivery into targets or protecting the vectors.
In the last decade many works that focused the attention on gene delivery were published; the
most recent and significant studies are here summarized.
Many researchers have studied the recombinant adeno-associated viral (rAAV) carriers as adapted
gene transfer vectors to direct human cartilagine in regenerative medicine [99–101]. However, their use
is limited cause their rapid neutralization by the presence of antibodies or heparin which prevent their
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binding to the viral receptor, present on the cell surface. In this regard, based on the use of polymeric
biocompatible materials the combining of direct rAAV-mediated gene transfer with tissue engineering
approaches, may offer efficient alternatives.
In this study [102] the possibility of providing rAAV to cartilage regenerative cells via
self-assembled poloxamers was evaluated. The formulations consisted of P188 and P407 (2% w/v i.e.,
above CMC)/rAAV or poloxamine/rAAV were directly incubated within monolayer cultures of hMSCs,
cartilagine regenerative cells. At thisoptimized concentration the two poloxamers were more efficient
in increasing gene expression over time than a treatment lacking them.
The highest rAAV gene transfer occurred when the PEO/PPO ratio was shifted to hydrophilicity
(HLB > 24) using a concentration above CMC (2%) (89.5–94.6% efficiencies with up to 2.7-fold increase in
transgene expression for at least 21 days, suggesting that micelles may be better carriers than unimers).
In another paper [103], lentiviral vectors (LV) used for the transduction of human and nonhuman
cells were taken into consideration. The optimal transduction conditions for efficient LV gene delivery
into target cells depended on a number of factors, including cell density, purity of lentiviral preparation,
virus transduction units (TU), multiplicity of infection (MOI) and presence of adjuvants that facilitate
transduction [104–106]. These researches identified and validated novel adjuvants for improving
transduction efficiency, in particular five representatives poloxamers (P402, P235, P188, P407, and
P338). P338 proved to be the best choice since it produced low toxicity and effective viral transduction,
especially in difficult-to-transduce cells of T-cell origin.
Further application strategies with poloxamer regard cancer therapy [4]. Poloxamers have gained
interest in the field of oncology because of their ability to developed stable systems with the capability
of efficient drugs encapsulation and deliver. They usually present small sizes and self-assembling
behavior in micellar systems in an aqueous medium, good stability in physiological medium and they
avoid the deactivation by RES organs improving consequently drug bioavailability [22,107].
In this biomedical and pharmaceutical area the most recent works in the literature are reported.
The first one concerned the use of poloxamer micelles containing a dye (CyFaP) as photo-acoustic
imaging (PAI) contrast for mammary neoplastic tissue [108]. In this formulation, dye was inserted in
P407 (10% w/v) micelle dropwise under constant stirring. Serum stability studies, cell viability assays,
deep tissue penetration and in vivo biodistribution studies were performed. This work has shown that
poloxamer micelles are effective for PAI as they penetrate more deeply into breast cancer tissue and are
also useful for lymphatic mapping.
The second work [109] explored the anticancer activity of Salinomycin (SAL), an antibiotic isolated
from Streptomyces albus [110], that has recently been reported as being effective against tumor cells
and mainly to inhibit growth of a specific cancer cell sub-population: CSC. The main goal of the
research was the encapsulation of SAL into an innovative poloxamer micelles (PM) system and a further
evaluation of in vitro PM-SAL delivery in bacterial and in eukaryotic tumor cells. PM formulations
containing P407 and SAL in different amounts were defined with a two multivariate experimental
design (DoE) to get the best preparation conditions. Micelles were characterized for size by dynamic
light scattering, for their zeta potential and for the encapsulation efficiency. Their in vitro activity was
conducted in bacterial cell culture and A549 (adenocarcinoma cell line) cell culture. In conclusion, these
micelles seem to be able to deliver SAL into human cancer cells promoting a high drug intracellular
accumulation, greatly decreasing toxicity on healthy cells.
Finally, a combined study between radiation therapy and systemic chemotherapeutics to provide
both local radiosensitization and systemic control of tumor disease has been reported [111,112]. This
study showed the development of a single micelles formulation consisting of multiple poloxamers
(MPMs) containing PARP (poly ADP- ribose polymerase) inhibitor talazoparib (Tal) and PI3K
(phosphoinositol-3-kinase) inhibitor buparlisib (Bup). When administered during a radiotherapy
cycle, that would increase the therapeutic activity of the two drugs in a preclinical model [113]. The
performed formulation was made of poloxamer mixture (P103 and P407) obtaining micelles (MPMs)
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via a modified nanoprecipitation method [114]. MPMs were characterized by dynamic light scattering,
to determine size, zeta potential and polydispersity, and by transmission electron microscopy (TEM).
It was also observed that MPMs modulate drug release depending on pH; this behavior is a very
useful tool, as the change in pH at tumor level (pH 6.8) would result in a faster release than what occurs
when they are circulating in the blood stream (pH 7.4). Furthermore, metabolic assays confirmed that
the use of both Tal and Bup synergistically enhanced in vitro cytotoxicity. The in vitro therapeutic
activity of the two drugs was studied by a colony-forming assay and a DNA damage assay.
In vivo experiments have shown that the administration of this new MPMs formulation during the
course of radiotherapy gave promising results into the enhanced tumor control. The results of this study
confirmed that it is important to carry on the development and advancement of combination therapies,
especially with the aim of enhancing the outcomes of patients in late-stage and metastatic disease.
6. Summary
Poloxamers are peculiar synthetic tri-block copolymers composed of two poly(ethylene oxide)
units and a poly(propylene oxide) one with amphiphilic properties. The dual character, confers to the
copolymers interesting properties that can be controlled and changed by different PPO/PEO ratios.
These polymers exhibit thermogelling behavior at strategical physiological temperatures.
The most used and studied poloxamer P407, at a concentration of 20% w/w in water, is able to
convert the solution to a clear gel by warming the system from room (25 ◦C) to body temperature
(near 37 ◦C). This thermoresponsive feature has made it attractive for several applications including
injectable and topical pharmaceutical formulations, where the material may flow through an applicator
or syringe before forming a gel upon contact with the body (35–37 ◦C).
Because of their biocompatibility and nontoxicity poloxamers have been widely utilized in
biomedical applications. In this review their usefulness as thermoreversible hydrogels in the most
significant routes of administration (i.e., ocular, transdermic and vaginal route) was reported. Moreover,
the latest frontiers have been highlighted for what concerns poloxamers employed in tissue engineering
and in gene and cancer therapy.
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